Nature CommunicationsImmunologyPeer-reviewed journal article
Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad Neuraminidase Inhibition by Human Antibodies
Julia LederhoferiD, Andrew J. BorstiD, Lam Nguyen, Rebecca A. GillespieiD, Connor WilliamsiD, Emma L. WalkeriD, Julie E. RaabiD, Christina Yap, Daniel EllisiD, Adrian CreangaiD, Hyon‐Xhi TaniD, Thi H. T. DoiD, Michelle RavichandraniD, Adrian B. McDermottiD, Valerie Le SageiD, Sarah F. AndrewsiD, Barney S. GrahamiD, Adam K. WheatleyiD, Douglas S. ReediD, Neil P. KingiD, Masaru KanekiyoiD
Abstract
Influenza has been responsible for multiple global pandemics and seasonal epidemics and claimed millions of lives. The imminent threat of a panzootic outbreak of avian influenza H5N1 virus underscores the urgent need for pandemic preparedness and effective countermeasures, including monoclonal antibodies (mAbs). Here, we characterize human mAbs that target the highly conserved catalytic site of viral neuraminidase (NA), termed NCS mAbs, and the molecular basis of their broad specificity. Cross-reactive NA-specific B cells were isolated by using stabilized NA probes of non-circulating subtypes. We found that NCS mAbs recognized multiple NAs of influenza A as well as influenza B NAs and conferred prophylactic protections in mice against H1N1, H5N1, and influenza B viruses. Cryo-electron microscopy structures of two NCS mAbs revealed that they rely on structural mimicry of sialic acid, the substrate of NA, by coordinating not only amino acid side chains but also water molecules, enabling inhibition of NA activity across multiple influenza A and B viruses, including avian influenza H5N1 clade 2.3.4.4b viruses. Our results provide a molecular basis for the broad reactivity and inhibitory activity of NCS mAbs targeting the catalytic site of NA through substrate mimicry.
- organism: human
- assay: structural biology
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 8
- FWCI
- 4.89
- Field percentile
- top 4%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans
P. Rijal, B. B. Wang, … K.-Y. A. Huang·bioRxiv·Jun 26, 2019
- Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availability
Mirte N. Pascha, Marlies Ballegeer, … Cornelis A. M. de Haan·bioRxiv·Sep 3, 2024
- Structure and function of a cross-neutralizing influenza neuraminidase antibody that accommodates recent N2 NA Asn245 glycosylation
Xueyong Zhu, Ahmed Magdy Khalil, … James J. Kobie·Communications BiologyPeer-reviewed·Oct 6, 2025
- Monoclonal antibodies targeting the influenza virus N6 neuraminidase
S. Strohmeier, F. Amanat, … F. Krammer·bioRxiv·Feb 15, 2021
- Structural basis of broad protection against influenza virus by a human antibody targeting the neuraminidase active site via a recurring motif in CDR H3
Gyunghee Jo, Seiya Yamayoshi, … Andrew B. Ward·Nature CommunicationsPeer-reviewed·Aug 1, 2025
- Neuraminidase-Based Cross-Protective Immunity against H5N1 Influenza Viruses in Humans
Iván Sanz-Muñoz, Carlos J. Ciria-Gil, … Aitor Nogales·bioRxiv·Jun 12, 2026